“Antibiotics of the Future” – Wall Street Journal, 16 December 2013

Misuse of antibiotics in people and livestock is rampant, and has caused the formation of antibiotic-resistant germs to speed up. As a result, scientists are trying to create new antibiotics that will fight the germs that existing antibiotics can’t fight.

Scientists are using varying methods to develop new antibiotics, such as adding silver, which can increase the antibiotics’ ability to combat germs. Researchers are also employing the bacteria’s own genetic sequencing to accelerate the creation of more powerful drugs.

In the US, almost two million people are infected yearly by antibiotic-resistant bacteria, resulting in thousands of deaths. It’s natural for antibiotics to become less efficient over time: bacteria develops a resistance, which means new antibiotics need to be created regularly. Both misuse of antibiotics and a decline in antibiotic development since 1990 have added fuel to the fire.

Researchers now have the capability to develop new antibiotics by studying germs’ genomes and looking for certain gene patterns. Most antibiotics are cultivated from the bacteria’s toxins—analyzing a germs’ genes has proven to be a great, albeit slow, method to creating new antibiotics.

Researchers are also looking for ways to render germs powerless. A person becomes infected when the bacteria’s population grows to a certain amount; scientists are trying to figure out if there’s a way to break communication between the individual microbes. In addition, scientists are trying to subdue toxins and other signaling molecules that are fundamental for an infection to advance.

February 28, 2014

Fluid Management Systems

Copyright 2014   All rights Reserved by Fluid Management Systems, Inc.

www.fluidmanagementsystem.com     subodh@fluidmanagementsystem.com

Social Share Toolbar

Bridging the Gap between Animal Health and Human Health — NIAA Antibiotic Symposium White Paper Released

The National Institute for Animal Agriculture (NIAA) recently published a white paper for the 2013 symposium, Bridging the Gap between Animal Health and Human Health, a continuation and extension of two previous symposiums, Antibiotic Use in Food Animals: A Dialogue for a Common Purpose in 2011 and A One Health Approach to Antimicrobial Use & Resistance: A Dialogue for a Common Purpose in 2012.

The goals of the 2013 and the past symposiums have been the same, supportive of the NIAA’s mission to continue forging a new path for a strong relationship between farmers, veterinarians, experts, drug companies and others, in order to resolve antibiotic resistance.

Twenty presentations were given by a range of experts on antibiotic use and resistance, which addressed many items, including the following:

  1. Due to wide mistreatment of antibiotics and a wide array of viewpoints, our knowledge of antibiotic resistance requires further study and clarification. There are many facets to antimicrobial resistance; if you believe you have a 100% understanding, then you haven’t received an accurate explanation.
  2. The relationship between animal, human and environmental health is compelled by the following: 1) the fact that antimicrobial resistance is bound to happen—its existence is natural and present, regardless of the use of antimicrobials; 2) when an antibiotic gains access to the ecosystem, there is a possibility that it will advance antibiotic resistance.
  3. Antibiotic resistance can be transferred between animals and humans, and vice versa.
  4. Antibiotic resistance is present in livestock, humans and companion animals, or pets.
  5. Antibiotic resistance is a global issue, not just an issue in the US.
  6. Meat manufacturing needs to follow current regulations, including correcting our mistreatment of animal antibiotics.
  7. Working towards decreasing the prevalence of antibiotic resistance requires collaboration. We must ask ourselves, “How does human health, environmental health and animal health work together to address antibiotic use and resistance?”.
  8. And much more.

(source)

Though the symposium brought key experts in human and veterinary medicine together to debate on the best approach to solving antibiotic resistance, there is still much to be done. We must closely observe and gain a better understanding of antibiotic resistance, as well as improve the motivation for advancing new antibiotics. Antibiotic resistance doesn’t originate from one source; the best way to focus on the issue is to streamline the system and eradicate any confusion.

Read all our blog posts on Human-Animal Health

Read the Bridging the Gap between Animal Health and Human Health White Paper

January 28, 2014

Fluid Management Systems

Copyright 2014   All rights Reserved by Fluid Management Systems, Inc.

www.fluidmanagementsystem.com     subodh@fluidmanagementsystem.com

Social Share Toolbar

“Meat Industry Won’t Fight Antibiotics Rule” – Wall Street Journal, 12 December 2013

Last week, the FDA introduced new policy that aims to curtail growth promotion antibiotics used on livestock. The use of these antibiotics on animals has been linked to the generation of antibiotic-resistant bacteria in humans.

While farmers and the meat industry support the FDA, neither think the new regulations will have an impact on the livestock industry. The FDA’s regulations deem it illegal to use antibiotics for growth promotion purposes, only allowing for antibiotic use when medically necessary. While the FDA now requires veterinarians to supervise antibiotic use on livestock, farmers will still be able to use antibiotics for preventative measures, especially in feed and water.

According to the FDA, almost 30 million pounds of antibiotics were used on livestock in 2011, a 2% increase from 2010. In 2011, around 7.3 million pounds of antibiotics were used to medicate people.

The FDA’s new policy is not mandatory for drug companies, yet animal drug companies like Zoetis and Elanco have complied. The guidelines request that drug companies remove any wording from their labels that implies that a drug promotes growth.

These are the steps in the right direction to protect animal and human health while enhancing public image for livestock and drug companies.

December 27, 2013

Fluid Management Systems

Copyright 2013   All rights Reserved by Fluid Management Systems, Inc.

www.fluidmanagementsystem.com     subodh@fluidmanagementsystem.com

Social Share Toolbar

“New Antibiotics Guidelines for Livestock Producers Explained” – The Cattle Site, 7 August 2013

Use of antibiotics with livestock has been long talked about in the animal health community; and finally, the FDA is introducing antibiotic guidelines for farmers and livestock producers to follow, in order to prevent the spread of antibiotic resistance to humans.

Farmers often use antibiotics as a way to help their livestock gain weight, while also preventing disease, but farmers aren’t required to report their use of antibiotics. The misuse or overuse of antibiotics can promote antibiotic resistance in humans, transferring resistant bacteria to humans. The goal of the FDA’s new regulations is to foster appropriate use of antibiotics in livestock.

The FDA has determined which specific antibiotics will have requisite veterinary oversight. They are going to work with drug companies to reprint drug labels that claim to boost feed efficiency and growth promotion, instead highlighting disease prevention, control and treatment. In addition, the FDA will concentrate on making it easier for livestock producers to acquire Veterinary Feed Directive drugs, which are used in animal feed; the use of Veterinary Feed Directive drugs are supervised by licensed vets.

Click here for the list of antibiotics included in the call for veterinary oversight.

Read all of our entries related to Human-Animal Health.

Conceived, Developed and Written by Dr. Subodh Das and Tara Mahadevan

August 28, 2013

Fluid Management Systems

Copyright 2013   All rights Reserved by Fluid Management Systems, Inc.

www.fluidmanagementsystem.com     subodh@fluidmanagementsystem.com

Social Share Toolbar

Fluid Management Systems Granted Utility Patent

photo 4On June 18th, the US Patent and Trademark Office (USPTO) granted FMS a utility patent for a system that manages inventory through a non-invasive measurement process. USPTO also approved a trademark — VETrak — for commercial applications. FMS has several pending provisional and utility patents for human- and animal-health applications.

The measurement system developed by FMS is envisioned as a system to track injectable medications administered in hospitals, clinics and doctors’ offices. The technology resulting from this vision is highly adaptable; the first iteration of the technology will be implemented in the animal-health market.

photo 8

FMS is currently employing commercial VETrack units at swine farms in Illinois and Iowa. FMS is also in discussions with Lexington-based equine and pharma-manufacturing companies to expand the technology’s applicability to additional animal farms, as well as the human-health field.

Conceived, Developed and Written by Dr. Subodh Das and Tara Mahadevan

July 19, 2013

Fluid Management Systems

Copyright 2013   All rights Reserved by Fluid Management Systems, Inc.

www.fluidmanagementsystem.com     subodh@fluidmanagementsystem.com

Social Share Toolbar

“Do antibiotics in animal feed pose a serious risk to human health?” – Medical Xpress, 10 July 2013

Medicated animal feed and water, and the risk they pose to humans, is still widely debated in the agriculture industry, as many are on opposing sides.

Though there are moves to create new antibiotics that would allow for less antibiotic resistance, medical experts suggest that scaling down on antibiotic use overall should be our first step. From 2009-2011, 72% of antimicrobials sold in the US were used to medicate water and animal feed. Such additives are regularly given to animals, in order to boost growth and curb disease, and are often unnecessary since livestock are typically healthy; livestock living conditions — sometimes crowded and unhygienic — are what can encourage disease.

In April, we wrote about a new study by Britain and Denmark that showed that bacteria does indeed move from animals to humans. Denmark, the global forerunner in pork exports, seems to be an expert in the arena of antimicrobial use in livestock production: in 1994, Denmark decreased its usage of antimicrobials by 60%, while also expanding its pork production by 30%. From the British and Danish study, we can easily glean that regular antibiotic use in livestock production can breed resistance.

Politics also play a heavy hand in this debate, and contribute to an unwillingness to act.

See our previous blogs on this subject:
Antibiotics and the Meat We Eat
Study Shows Bacteria Moves From Animals to Humans
Antibiotic-Resistant Bacteria Surround Big Swine Farms in China & US

Conceived, Developed and Written by Dr. Subodh Das and Tara Mahadevan

July 11, 2013

Fluid Management Systems

Copyright 2013   All rights Reserved by Fluid Management Systems, Inc.

www.fluidmanagementsystem.com     subodh@fluidmanagementsystem.com

Social Share Toolbar

“Antibiotics and the Meat We Eat” – New York Times, 27 March 2013

The agricultural industry’s use of antibiotics in their livestock has been a hot button topic the last few months, and only getting hotter. While the agriculture industry overwhelmingly denies that antibiotic-resistant bacteria can be transferred from livestock to humans, a British-Danish report from last month shows that bacteria does has the ability to move from animals to humans.

As we wrote in a previous post in November, “Farm Use of Antibiotics Defies Scrutiny“, responsibility for regulating antibiotic use is splintered among multiple agencies: the FDA, USDA and CDC. The FDA polices drugs, a role they carry out by overseeing the meat sold in our supermarkets, and by monitoring the existence of bacteria that are resistant to antibiotics. The FDA is trying to get a handle on the kinds of antibiotics that are being fed to livestock, but to no avail — livestock facilities are not legally required, and are vehemently opposed, to divulge details about what drugs are administered to which animals, and in what amounts.

It seems as this point that the situation could be a matter of life and death. In 2011, the agricultural industry bought almost 30 million pounds of antibiotics — 80% of the US’s 2011 antibiotic sales — for animal use, the biggest quantity ever purchased. The drugs are mostly given to animals at low dosages in order to encourage growth, and to contain any sicknesses they might contract by living in such close quarters of each other and their waste. However, feeding livestock low levels of antibiotics can actually breeds antibiotic-resistant diseases.

In 2008, Congress forced drug companies to report to the FDA the amount of antibiotics they sold to agricultural facilities. Again, no information was released on what drugs were given to which animals, in what amounts and why.

The Senate Committee on Health, Education. Labor and Pensions reauthorized the Animal Drug User Fee Act (ADUFA) for 2013, requiring veterinary-drug companies to pay fees to the FDA as a way to financially support the agency. Two Democrats from the House have introduced new legislation that would give FDA the authority to amass more data from drug companies, as well as make food producers reveal how frequently they give low doses of antibiotics to animals, so as to spur growth and offset poor conditions.

We believe that in order to lower societal costs, and protect animals and humans, open and objective debate needs to continue among all stakeholders.

Conceived, Developed and Written by Dr. Subodh Das and Tara Mahadevan

April 29, 2013

Fluid Management Systems

Copyright 2013   All rights Reserved by Fluid Management Systems, Inc.

www.fluidmanagementsystem.com     subodh@fluidmanagementsystem.com

Social Share Toolbar

“Drug Makers’ Push into Injectables Could Ease Shortages” – Wall Street Journal, 26 March 2013

Healthcare and drug companies are looking to join a market largely held by hospitals: injectable drugs, a $7 billion industry that often experiences shortages.

Drug mogul Becton Dickinson (BD), for example, plans on introducing 20-30 new injectable medicines to the US over the next few years, some of which have been in short supply. International drug companies are also seizing the market. Jordan-based Hikma Pharmaceuticals will launch 5-10 products in the next few years, also introducing a few of which have been scarce.

Companies like BD are attracted to this market because of the supply issue; and while sterilizing injectable drugs can prove difficult, the payoff is big: almost one billion vials  are sold each year. However, companies might have to wait for the long-run, as producing sterile medicines can be expensive with low profits. Many companies left the market due to the cost, leaving some drugs to just one manufacturer. In addition, manufacturing problems, supply constraints and government investigation of manufacturing plants have pushed many drug firms to abandon facilities or slow down production.

What resulted was an even larger shortage in 2011: 183, as opposed to 23 five years earlier. According to the FDA, the shortages fell to 84 in 2012, partly because Pfizer began manufacturing limited cancer injectables and some plants, which were previously shut down, reopened.

Yet, in order to turn a profit, many companies are looking into raising prices by 10%. This would greatly affect hospitals and their drug buyers, who will most likely fight the increases. In order to cut costs and availability, drug companies should consider  producing and selling drugs in multi-dose vials. Fluid Management Systems, Inc. has the technology to manage and monitor injectable drug inventories in multi-dose vials.

Conceived, Developed and Written by Dr. Subodh Das and Tara Mahadevan

April 10, 2013

Fluid Management Systems

Copyright 2013   All rights Reserved by Fluid Management Systems, Inc.

www.fluidmanagementsystem.com     subodh@fluidmanagementsystem.com

Social Share Toolbar